Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results

Last Modified: 11/14/2008 First Published: 9/1/2002


1.		Phase I/II Randomized Study of Vaccination With Melanoma Antigen-Pulsed Dendritic Cells Versus Melanoma Antigens With QS21 Adjuvant in Patients With Surgically Resected Stage IIB, IIC, or III Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NYU-RUH-NBH-0428-0401 RUH-NBH-0428-0401, NCI-5636, NCT00045383, 5636

Last Modified: 11/14/2008 First Published: 11/20/2003


2.		Phase I/II Study of Vaccination With Autologous Monocyte-Derived Dendritic Cells Transfected With RNAs Encoding For Melan-A, MAGE-3, and Survivin Antigens in Patients With Stage IV Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				ERLANGEN-DERMA-ER-DC-06 EU-20317, NCT00074230


3.		Dendritic Cell Based Therapy of Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				UR0414 NCT00197860


4.		Dendritic Cell Based Therapy of Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				MM0413 NCT00197912


5.		WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				HaemaCBFWT102 Carreras 04/25f, NCT00153582


6.		A Study to Evaluate the Ability of Lupron Depot to Enhance Immune Function Following Bone Marrow Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Supportive care				Active				18 to 50				Pharmaceutical / Industry				L-BT04-093 NCT00275262


7.		WT1 Peptid Vaccination in Carcinomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				HaemaCBFWT104 EU, NCT00153608

Last Modified: 11/18/2008 First Published: 8/24/2004


8.		Phase I Randomized Pilot Study of Fludarabine Followed By Vaccination Comprising Modified gp100 Peptide, Montanide ISA-51, and Keyhole Limpet Hemocyanin Combined With Autologous Peripheral Blood Mononuclear Cell Reinfusion in Patients With Unresectable or Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				PPMC-IRB-02-99 NCI-6361, 6361, NCT00091143

Last Modified: 11/18/2008 First Published: 10/14/2006


9.		Phase I Randomized Study of Intralymphatic Autologous Type-1-Polarized Dendritic Cell Vaccine Versus Autologous Mature Dendritic Cell Vaccine Loaded With Antigenic Peptides and Proteins in Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Diagnostic, Treatment				Active				18 and over				NCI				PCI-UPCI-03-118 7089, NCI-7089, PCI-IRB-0409071, NCT00390338


10.		Vaccination With Tetanus and KLH to Assess Immune Responses.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Biomarker/Laboratory analysis, Treatment				Active				18 to 55				NCRR				NCRR-M01RR00400-0626 M01RR00400, NCT00000105

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute